Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Arrowhead Pharmaceuticals (ARWR)
NASDAQ:ARWR
RESEARCH TOOLSreports
Holding ARWR?
Track your performance easily
Earnings Data
Report Date
Feb 05, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.41Last Year’s EPS
-1.24Same Quarter Last Year
Moderate Buy
Based on 10 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Dec 11, 2018
|% Change Since: -4.85%
|Next Earnings Date:Aug 07, 2018
Earnings Call Sentiment|Positive
The earnings call presented a mix of transformative achievements and financial challenges. The significant partnership with Sarepta, positive clinical developments, and a strong financial outlook for the future were major highlights. However, increased losses, halted development of a key program, and a notable decline in revenue were concerning issues. Overall, the highlights outweigh the lowlights given the strategic advancements and financial improvements expected from the new partnership.Company Guidance
During Arrowhead Pharmaceuticals' recent earnings call, significant guidance was provided with a focus on their new collaboration with Sarepta Therapeutics. The deal involves a $500 million upfront cash payment, a $325 million equity investment at a 35% premium, and another $250 million spread over five years. Arrowhead could potentially receive up to $11 billion in total deal value, including $300 million in near-term payments contingent on certain clinical milestones, as well as additional development and sales milestone payments and royalties. This partnership aims to advance multiple RNAi-based programs targeting various diseases, including those in the cardiometabolic and CNS spaces. Arrowhead expects that this deal will fund them through 2028, supporting their pipeline and potential commercial launches, particularly for their lead program, plozasiran. The company also highlighted its strategy to focus on cardiometabolic programs while considering partnerships for non-core assets.Transformational Partnership with Sarepta
Arrowhead and Sarepta entered into a licensing and collaboration agreement that could exceed $11 billion in value. The deal includes a $500 million upfront cash payment, a $325 million equity purchase at a 35% premium, and potential milestone payments ranging from $110 million to $410 million per program.
Plozasiran NDA Submission
Arrowhead submitted a New Drug Application to the FDA for plozasiran as a treatment for familial chylomicronemia syndrome (FCS). The application benefits from the FDA's breakthrough therapy designation, potentially speeding up the review process.
Strong Financial Position
Arrowhead's cash and investments at the end of fiscal 2024 were $681 million, which is expected to increase significantly with the Sarepta deal, extending their cash runway into 2028.
Positive Phase-3 Data for Plozasiran
The PALISADE study showed an 80% reduction from baseline in triglycerides with plozasiran, meeting its primary endpoint and significantly reducing the incidence of acute pancreatitis.
Expanding Cardiometabolic Focus
Arrowhead is focusing resources on a range of cardiometabolic programs, with a potential first commercial launch of plozasiran in 2025 and additional indications in severe hypertriglyceridemia (SHTG) by 2026.
---
ARWR Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
ARWR Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 26, 2024 | $21.05 | $26.15 | +24.23% |
| Aug 08, 2024 | $25.85 | $23.41 | -9.44% |
| May 09, 2024 | $24.72 | $22.08 | -10.68% |
| Feb 06, 2024 | $33.20 | $31.65 | -4.67% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Arrowhead Pharmaceuticals (ARWR) report earnings?
Arrowhead Pharmaceuticals (ARWR) is schdueled to report earning on Feb 05, 2025, TBA Not Confirmed.
What is Arrowhead Pharmaceuticals (ARWR) earnings time?
Arrowhead Pharmaceuticals (ARWR) earnings time is at Feb 05, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ARWR EPS forecast?
ARWR EPS forecast for the fiscal quarter 2025 (Q1) is -0.41.
---